While some tumor uptake was observed in CEA− patients (cohort D), the extent was lower than for CEA+ patients (cohort C mean %ID/mLpeak CEA− 3.6 ×∙10–3 ± 1.7 ×∙10–3 vs. CEA+ 6.7 ×∙10–3 ± 5.9 ×∙10–3, P = 0.15). The gene discussed is CEACAM5; the disease is neoplasm.